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Next-generation sequencing (NGS)’s crucial role in supporting genetic diagnosis and
personalized medicine leads to the definition of Guidelines for Diagnostic NGS by
the European Society of Human Genetics. Factors of different nature producing
false-positive/negative NGS data together with the paucity of internationally accepted
guidelines providing specified NGS quality metrics to be followed for diagnostics
purpose made the Sanger validation of NGS variants still mandatory. We reported the
analysis of three cases of discrepancy between NGS and Sanger sequencing in a cohort
of 218 patients. NGS was performed by Illumina MiSeq R© and Haloplex/SureSelect
protocols targeting 97 or 57 or 10 gene panels usually applied for diagnostics.
Variants called following guidelines suggested by the Broad Institute and identified
according to MAF <0.01 and allele balance >0.2 were Sanger validated. Three out
of 945 validated variants showed a discrepancy between NGS and Sanger. In all three
cases, a deep evaluation of the discrepant gene variant results and methodological
approach allowed to confirm the NGS datum. Allelic dropout (ADO) occurrence during
polymerase chain or sequencing reaction was observed, mainly related to incorrect
variant zygosity. Our study extends literature data in which almost 100% “high quality”
NGS variants are confirmed by Sanger; moreover, it demonstrates that in case of
discrepancy between a high-quality NGS variant and Sanger validation, NGS call should
not be a priori assumed to represent the source of the error. Actually, difficulties (i.e.,
ADO, unpredictable presence of private variants on primer-binding regions) of the so-
called gold standard direct sequencing should be considered especially in light of the
constantly implemented and accurate high-throughput technologies. Our data along
with literature raise a discussion on the opportunity to establish a standardized quality
threshold by International Guidelines for clinical NGS in order to limit Sanger confirmation
to borderline conditions of variant quality parameters and verification of correct gene
variant call/patient coupling on a different blood sample aliquot.
Keywords: high-throughput sequencing, next generation sequencing, Sanger sequencing, sequencing validation,
discrepancy, allelic drop-out, variant call quality
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INTRODUCTION
Since their first appearance in the mid-2000s, next-generation
sequencing (NGS) technologies have marked a new era
in investigating genetic complexity. Their continuous
implementation is universally perceived as crucial for their
increasingly important contribution in genetic research as well
as in the diagnostic field and for the overall benefit they can
represent for patients management (Goodwin et al., 2016).
Widely used NGS platforms have in common the ability to
perform and capture data deriving from a massively parallel
sequencing of millions of reactions simultaneously (Mardis,
2008). Continuous and impressive developments in these
technologies are offering the opportunity to interrogate changes
in DNA and RNA molecules at such a level of precision that the
role of NGS in supporting the clinical management of patients
and in personalized medicine has been addressed, thus leading
to the Guidelines for Diagnostic Next Generation Sequencing
(Matthijs et al., 2016) by the European Society of Human
Genetics (ESHG). One of the main statements of the document
focuses on the challenges these technologies bring in terms of
data management and on acceptable, standardized validation of
the tests, as NGS is not an error-free technique. Apart from those
factors regarding the starting material (e.g., quality and storage
conditions of the starting biological material as well as molecules
interfering with DNA extraction from blood of patients treated
with drug or medication) or the analytical confounders [GC- and
AT-rich areas, repeat sequences, large (>20-bp) deletions (Ilyas,
2017)], a significant issue in NGS is essentially represented by the
accuracy of the different bioinformatic pipelines in (a) filtering
low-quality reads, (b) discriminating clinically relevant variation
from background “noise” (due, for instance, to spontaneous PCR
errors and deamination), and (c) accurately aligning the reads
to a reference sequence. Also, a low read depth (below 10 reads
per base on average for whole-exome sequencing on Illumina
platforms, 20–30 reads for gene panel sequencing on Ion Torrent
and Illumina) determines false-positive results due to sequencing
errors especially in GC-rich regions (McCourt et al., 2013; Strom
et al., 2014; Beck et al., 2016; Zheng et al., 2019). Further, clinically
relevant mutations can be missed (false-negative results) as some
exons may be not completely represented or sufficiently covered
(Sikkema-Raddatz et al., 2013; Beck et al., 2016). For those
reasons, together with the paucity of internationally accepted
regulatory guidelines providing specified NGS quality metrics to
be followed in the clinical setting, Sanger sequencing validation
(costly, time consuming, and not error-free) of NGS detected
variants is mandatory in routine diagnostics [ESGH, Matthijs
et al., 2016; NGS sequencing, indications for clinical application,
Società Italiana di Genetica Umana (SIGU), 2016]. However,
the necessity of validating genetic variants identified through
high-performance instruments, which are increasingly accurate
and affordable, with a more expensive technology, raised a
question about the actual cost-effectiveness of such an approach,
both in research and in diagnostic fields. Several recent reports
suggested that NGS data, reaching established quality scores, are
as accurate as Sanger sequencing (McCourt et al., 2013; Sikkema-
Raddatz et al., 2013; Strom et al., 2014; Baudhuin et al., 2015;
Beck et al., 2016; Zheng et al., 2019) as the latter was able to
confirm nearly 100% of NGS detected variants at an initial or
a second sequencing run. A low number of NGS variants were
not validated even after a second Sanger run. These variants
were found to show relatively low-quality scores for their NGS
calls. In the current study, we analyzed three cases of discrepancy
between the NGS-generated datum and the subsequent first
round of Sanger validation. Discrepant data resulted from the
validation of 945 rare genetic variants identified in 218 patients.
MATERIALS AND METHODS
DNA Isolation
Genetic analysis was conducted on a cohort of 218 patients
admitted to the Advanced Molecular Genetics Laboratory,
Department of Experimental and Clinical Medicine, Careggi
Hospital-University of Florence. Informed consent was obtained
from subjects included in the study, and the study was approved
by the Careggi Hospital Ethics committee (registration number
CEAVC OSS 16.291 and 11114).
Peripheral venous blood was collected in EDTA-coated
vacutainer tubes and was stored at −20◦C. Genomic DNA
was extracted from blood samples using the Tecan R© Freedom
EVO R© liquid handling platform (Tecan Group Ltd., Switzerland)
and GeneCatcherTM gDNA 0.3–1 mL Blood Kit (Thermo
Fisher Scientific, United States). All procedures were performed
following the manufacturer’s protocols.
Next-Generation Sequencing and Variant
Selection
A targeted NGS was performed on three genes panels [97
(627,782 kbp) + 57 (241,143 kbp) + 10 (49,312 kbp) genes,
Supplementary Tables 1–3] applied in the diagnostic and
research routine for Marfan syndrome and related disorders,
familial dyslipidemia, and von Willebrand disease at the
Department of Experimental and Clinical Medicine, Section of
Critical Medical Care and Medical Specialities, University of
Florence, Italy. Oligo probes specific for the target gene regions
were designed using Agilent Sure Design (Agilent Technologies,
Santa Clara, CA, United States) in order to create a custom
target enrichment library of the selected genes. The capture
region comprised all coding exons and flanking intron sequences
(50 bp upstream and downstream at exon–intron junctions).
Amplicon sequencing libraries were prepared from 50 to 750 ng
of DNA per sample according to the SureSelectQXT (for largest
panel) and HaloPlexHS (for 57 and 10 gene panels) Amplicon
protocol (Illumina Inc., San Diego, CA, United States). The
pooled libraries were paired-end and sequenced on a micro
flow cell with V3 chemistry on a MiSeq instrument (Illumina
Inc., San Diego, CA, United States). The analytical pipeline
available in our laboratory was developed, implemented, and
validated for data analysis of targeted sequencing for diagnostic
purposes. Fastq files’ quality was checked with FASTQC. Adapters
and quality trimming were performed using Surecall Trimmer.
Trimmed reads were aligned to the human reference genome
(Human GRCh37/hg19) using BWA-MEM. Bam files’ quality
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was evaluated with Qualimap. Variant calling was performed
using GATK4 HaplotypeCaller in GVCF mode and the joint
genotyping tool GenotypeGVCFs. Variants were annotated using
VEP 99. Ninety-nine percent of targeted regions were covered.
Variants were filtered according to the phred quality score
(Q) ≥30 and a minimum coverage depth of 30×. Variants
called following guidelines suggested by the Broad Institute,
commonly accepted as standard, and identified according to
(a) MAF <0.01; (b) the potential pathogenetic/modulatory role,
according to variant classification recommendation (Richards
et al., 2015), literature genotype–phenotype association data
and/or biological plausibility; (c) in silico predictor tools (SIFT1;
PROVEAN2; PolyPhen-23; MutationTaster4; FATHMM5; Human
Splicing Finder6; NetGene27); (d) type of genetic variants; (e)
localization (exonic, splicing regions variants); and (f) allele
balance >0.2 were Sanger validated.
Validation by Sanger Sequencing
Specific flanking intronic primer pairs for the selected NGS
variants to be validated were designed using the Primer3
algorithm8, one of the most widely used primer designing tools
(Kumar and Chordia, 2015; Supplementary Table 4). Primer
sequences were checked for the presence of single-nucleotide
polymorphism (SNPs) on their complementary DNA strands
(visual inspection of sequences/SNP database)9. The resulting
amplicons were checked for sequence similarity throughout
the human genome using the Primer-BLAST tool10. The PCR
amplicons were then purified and Sanger sequenced. PCR
was performed in a final volume of 25 µl using FastStartTM
Taq DNA Polymerase, 5 U/µl Kit (Roche), 1 µl of dNTPs
(2.5 mM), 0.5 µl of each primer with a concentration
of 10 pmol/µl (Eurofins Scientific, Luxembourg), and 2 µl
genomic DNA in a concentration of approximately 50 ng/µl.
Amplicons were purified using an Exonuclease I 20 U/µl/FastAP
Thermosensitive Alkaline Phosphatase 1 U/µl (Thermo Fisher
Scientific, United States) mixture. Purified PCR products were
sequenced using the BigDye Terminator Kit v1.1 (Thermo Fisher
Scientific, United States) and ABI 3500Dx Sequencer (Applied
Biosystems, Foster City, CA, United States).
RESULTS
Among the total of 945 variants identified by NGS and selected
for Sanger validation, 942 (99,7%) were confirmed. The mean
coverage of experimental sessions was 173× for the SureSelect











98% of analyzable target bases; all variants met the phred-scaled
quality score Q ≥30. Three out of 945 variants (0.3%) showed
a discrepancy between the NGS datum and the subsequent
validation. Two variants were in the LTBP2 gene while the
third one involved the TGFB1 gene. All variants’ discrepancies
were related to their heterozygous/homozygous state. General
characteristics of mutations are reported in Table 1. The depth of
coverage for the three loci ranged from 173× to 199× (Table 1).
All 3 variants were called as heterozygous and presented
with balanced reads containing the wild-type or mutant allele
(percentages of mutant on total alleles range from 45 to 54%).
Patient 1 (P1) The first variant showing a discrepancy between
the NGS call and the subsequent Sanger validation involved
the LTBP2 gene (latent transforming growth factor-beta-binding
protein 2, OMIM∗602091). The missense LTBP2 mutation,
NM_000428.3:c.3979C > T (p.Arg1327Cys, rs758023418), had
a MAF of 0.0000088 in the ExAC database for the European
population. Primers were designed as previously described
(Supplementary Table 4). The Sanger electropherogram in
Figure 1A only revealed the presence of the mutated base (T at
3979 locus). The primer-binding regions were therefore checked
for the presence of SNPs on their complementary DNA sequences
and found negative. A second primer pair, external to the first
ones, was designed and used for the direct sequencing of the
new amplicons. The resulting electropherograms (Figure 1B)
showed the point mutation in the heterozygous state (as called
by NGS) as well as a 2-bp deletion within the forward primer-
binding DNA region (NM_000428.3:c.3908-98_3908-97delAG,
rs149267227, Figure 1C). This intronic variant had a MAF in the
European population of 0.0029.
Patient 2 (P2) LTBP2 second variant
(NM_000428.3:c.4203G > A) was a synonymous mutation
(p.Thr1401=) with a MAF of 0.00428 in the European ExAC
population. Primers were constructed, and the electropherogram,
deriving from the direct sequencing, did not reveal the point
mutation (only the wild-type base was present) (Figure 1D); in
addition, an 11-bp deletion was identified at the homozygous
state (Figure 1E). The combination of a second forward
primer and the original reverse one generated amplicons
whose electropherograms revealed both the mutation and
the deletion in the heterozygous state, as they were called by
NGS (Figures 1F,G; a schematic representation of the PCR
results and the primer localization on the DNA sequence is
reported in Supplementary Figure 1). Afterward, in order to
provide a further confirmation of data obtained, we performed
capillary electrophoresis using 6FAM labeled oligonucleotides
for both the original and the second forward primers. Amplicons
derived from the two different primer combinations (original
F primer + original R primer vs. second F primer + original R
primer) were analyzed along with a negative control (a DNA
sample belonging to the same experimental session and in which
the NGS call of the 11-bp deletion was negative). As shown in
Figure 2A, the original primer pair generated a single peak,
whose size matched the allele containing the 11-bp deletion,
which underwent a preferential amplification. On the other
hand, two different peaks resulted from the combination of the
second F primer + the original R one, whose sizes, 460 and
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TABLE 1 | Discrepant genetic variants analyzed in the study.
Gene Variant description dbSNP MAF_EU (ExAC) Chromosomic position (reads number per allele) QUAL*
P1 LTBP2 NM_000428 c.3979C > T p.Arg1327Cys rs758023418 0.0000088 chr14_74973455_C/T (0/1:107,92) 3197.33
P2 LTBP2 NM_000428 c.4203G > A p.Thr1401= rs150977380 0.00428 chr14_74971852_C/T (0/1:96,103) 4613.20
P2 TGFB1 NM_000660 c.169C > A p.Leu57Met rs1203938760 0.0000649 chr19_41858781_G/T (0/1:96,77) 2060.33
*phred-scaled quality score. MAF, minor allele frequency; EU, European.
FIGURE 1 | Direct sequencing electropherograms of the genetic variants in (A) LTBP2 (P1), original primers; (B) LTBP2 (P1), new primers; (C) LTBP2 deletion (P1),
new primers; (D) LTBP2 point mutation (P2), original primers; (E) LTBP2 deletion (P2), original primers; (F) LTBP2 point mutation (P2), second F primer + original R
primer; (G) LTBP2 deletion (P2), second F primer + original R primer; (H) LTBP2 (P2) intronic primers (the empty red rectangles indicate the original F primer
sequence; the empty red circles indicate the rs11846588 SNP proximal to the 3′ primer end); (I) TGFB1 (P3), original primers; and (J) TGFB1 (P3), new primers.
471 bp, were consistent with the presence of the 11-bp deletion
in that amplicon in the heterozygous state (Figure 2B). As
concerns the negative control, resulting peaks confirmed the
absence of the 11-bp deletion (Figures 2C,D). These data were
consistent with Sanger electropherograms deriving from the
combination of the second F primer and the original R one,
in which the 11-bp deletion was detected in the heterozygous
state (Figure 1G). Ultimately, a third, intronic, primer pair was
designed, in order to analyze the sequence of the original forward
primer. The resulting electropherogram was negative although it
actually revealed the presence of an SNP [NM_000428.3:c.4178-
224A > G, rs11846588, MAF_EU(ExAC) = 0.16] proximal to the
3′ primer end which was not previously detected (Figure 1H).
Patient 3 (P3) The last analyzed variant was a missense
mutation (NM_000660.6:c.169C > A, p.Leu57Met,
rs1203938760) involving the TGFB1 gene (transforming
growth factor-beta-1, OMIM∗190180) with a MAF in the
European ExAC population of 0.0000649. We proceeded with
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FIGURE 2 | Capillary electrophoresis results using 6-FAM-labeled original and external forward primers for LTBP2 variant amplification (P2): (A) P2, original F primer;
(B) P2, second F primer (C) negative control, original F primer; (D) negative control, second F primer. Peaks sizes are reported (red).
the Sanger validation ultimately obtaining an electropherogram
showing the variant in the homozygous state (Figure 1I). Once
again, we tested the primer pair used for the initial amplification
for their capacity to bind to SNPs and they resulted negative. We
therefore checked the experimental steps (initial amplification
or direct sequencing) in order to unequivocally identify the
phase in which the allelic loss took place. A restriction fragment
length polymorphism (RFLP) procedure was performed using
AluI enzyme cutting at a specific cleavage DNA site (5′. . .AG
↓CT. . .3′), which was identified by the NEBcutter V2.011 online
tool. The digestion reaction produces two different bands
profiles when visualized on a 3% agarose gel according to the
presence of the mutation at the heterozygous or homozygous
state (Figure 3A). The results of the AluI digestion performed
on our PCR product along with a negative control are shown
in Figure 3B. Our sample digestion profile demonstrated the
mutation to be in the heterozygous state, as the enzyme was able
to recognize three cleavage sites on the wild-type sequence and
two on the mutated one (51, 82, 171, 192, and 243 bp). A new,
internal primer pair was able to confirm the NGS call (Figure 1J).
DISCUSSION
In this study, we showed that high-quality NGS data robustness
could not benefit from Sanger validation due to errors occurring
in the technology.
The two last decades witnessed the rapid and impressive
advancements of high-throughput sequencing techniques, in
terms of both experimental workflows and data-processing
11http://nc2.neb.com/NEBcutter2/
pipelines dedicated to the management of the large volumes
of data generated by the various platforms. These technologies
provided indeed unprecedented opportunities for the study and
characterization of variants at the DNA and RNA level. Genetic
information is, in fact, investigated at such a level of precision that
the supporting role of these technologies for the study of complex
hereditary phenotypes has been implemented in both research
and diagnostics, also for the capability of different platforms to
analyze and interrogate large gene panels, exomes, and genomes
in times and costs that are progressively decreasing. Despite the
attempt made by the European Guidelines (2016) (Matthijs et al.,
2016) to provide the most useful indications to laboratories for
the evaluation and validation of variants identified by NGS, these
technologies still remain strictly dependent on computational
tools and bioinformaticians for the highly complex data analysis,
whose quality parameters may vary between laboratories as well
as the pipelines used for alignment, variant calling, filtering,
and annotation of variants. Current NGS guidelines do not
define quality parameters or concrete guidance for confirmatory
analysis. Therefore, Sanger sequencing is still considered the
gold standard for the validation of NGS genetic variants and an
essential step in the diagnostic routine. This kind of approach,
however, raised a question about the actual cost-effectiveness of
using very powerful platforms generating increasing quality data
at progressively decreasing costs and the need to apply a “time-
consuming” and not error-free [i.e., Allelic dropouts (ADOs)]
technique, whose cost does not decrease as quickly over time, to
validate the results.
Allelic dropout represents a significant cause of genotyping
errors, potentially determining substantial negative consequences
as it might lead to misdiagnosis of genetic diseases and
false-negative/positive results depending on the allele that drops
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FIGURE 3 | (A) Schematic representation of the AluI enzyme digestion on a wild-type, homozygous, and heterozygous mutated TGFB1 fragment; (B) 3% agarose
gel electrophoresis of the AluI enzyme digested and undigested P3 and WT control.
out (mutant or wild-type). ADO during PCR can be caused by
a variety of mechanisms, and a number of factors influencing its
rate have been described. Most ADO mechanisms are determined
by the presence of a single-nucleotide variant (SNV) situated
inside the primer-binding sequences on the targeted DNA, the
SNV causing the failure of the primer-template annealing and
the consequent amplification error. Concomitant presence of
a differential allelic methylation and G-quadruplex motifs in
some regions of the genome, DNA degradation leading to PCR
refractory breaks, imperfect PCR conditions preventing DNA
template accessibility, and presence of both homopolymer tracts
and pseudogenes were also described as potential determinants
of ADO or preferential amplification (Piyamongkol et al., 2003;
Stevens et al., 2017).
In the current study, 942 out of 945 (99.7%) high-quality
NGS variants identified in 218 subjects were validated by Sanger
sequencing. Our data are in keeping with previous studies,
suggesting that Sanger sequencing may not represent a necessary
step to validate NGS variants when dealing with data meeting
high-quality scores and an adequate depth of coverage. In fact,
several previous studies evaluating data from different NGS
platforms and approaches (targeted, exome, or whole-genome
sequencing) identified almost 100% Sanger validation rate on a
total of 14,495 variants (McCourt et al., 2013; Sikkema-Raddatz
et al., 2013; Strom et al., 2014; Baudhuin et al., 2015; Beck et al.,
2016; Zheng et al., 2019). In these studies, variants not validated
by Sanger sequencing did not match adequate quality scores
(Strom et al., 2014; Beck et al., 2016; Zheng et al., 2019). Both ours
and literature data move in the direction of a limited usefulness
of Sanger validation for NGS-derived variants associated with
robust quality scores, suggesting a re-consideration of its
application in routine diagnostics that should be limited to
validation of a specific clinical phenotype-associated variant,
quality assurance, and risk-avoidance purposes.
Beyond the previous issue, whether an accurate NGS approach
is used, our data demonstrated that potential well-known failures
affecting Sanger technology could further reduce its utility and
instead determine higher costs and delay in analysis conclusion
and laboratory report. In fact, among 945 variants, we identified
three discrepant variants. Despite their high-quality parameters,
namely, a balanced read number and high depths of coverage,
Sanger validation failed in confirming NGS datum: in all
three cases, NGS attributed a heterozygous state and Sanger
sequencing, a mutated homozygous state in P1 and P3, and a
wild-type homozygous state in P2. In the first case (LTBP2 gene
variant), the discrepancy was due to the presence of a small
deletion in the DNA region binding the forward primer of the
original pair. This deletion, potentially preventing the correct
primer annealing during the initial amplification phase, had a
frequency below 1% in the European ExAC population. This is
of note as this rarity could presumably allow some of the online-
automated primer-designing programs (which refer to dbSNP
databases to omit common variants) as well as a manual approach
to miss this kind of information during the primer construction
and its inclusion in their sequence. This aspect is similar for
private mutation of the patient in analysis. In fact, these variants
evade the “masking” phase of the primer construction process
where common variants are averted.
As concerns the further discrepant variant at the LTBP2
locus, we speculated that this discrepancy might be the
result of an alternative ADO phenomenon. In particular,
the presence of SNV outside primer sequences (non-primer-
binding-site SNVs) was demonstrated to promote a hairpin
formation of the PCR products, this secondary structure
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preventing further amplification and extension failures (Lam
and Mak, 2013). Lam and coworkers were in fact able
to demonstrate that a heterozygous NGS deletion (FAH,
NM_000137.1:c.1035_1037del) resulted in homozygosity at a first
Sanger sequencing run due to a non-primer-binding-site SNV
(FAH:c.961-35C, rs2043691) forming a strong hairpin structure
and leading to amplification failure of the wild-type allele.
Similarly, in our case, a non-primer-binding site SNP located
outside the 3′ end of the original F primer (Figure 1H) was
identified, which can be presumably held accountable due to the
discrepancy we observed.
Regarding the third case, we were instead able to demonstrate
that ADO had not occurred during the first amplification cycle
via traditional PCR but exclusively within the direct sequencing
reactions. Actually, even though Sanger sequencing by using
the original primers pair showed a mutated homozygous state,
RFLP procedure with the same primers showed the presence
of both alleles of TGFB1 mutation. The heterozygous state
was confirmed at a second Sanger validation run with new
primers. Our data do not define the fine mechanisms behind the
ADO we observed in case number 3 during Sanger sequencing
reaction; nevertheless, the previously mentioned mechanisms
(apart from those involving SNV inside or proximal to the
primer binding sequences) could be a potential explanation for
the discrepancies we observed. These phenomena could also be
impacted by intrinsic characteristics of Sanger technology which
uses chain-terminating di-deoxynucleotides under suboptimal
PCR conditions. Direct sequencing in fact employs a multiplex
PCR ensuring the amplification of several distinct DNA
fragments in a single reaction. This strategy necessarily operates
under less stringent PCR conditions which might adversely affect
amplification of individual loci or lead to secondary structure
formation, thus invalidating the synthesis of the newly generated
DNA strands (Piyamongkol et al., 2003).
CONCLUSION
In conclusion, our data suggest the chance of Sanger approach
errors that go beyond the presence of common variants. Actually,
both studies of Beck et al. (2016) and Zheng et al. (2019) had also
encountered this kind of criticism: in the first case, authors had
to re-sequence 19 discrepant variants, 17 of which were validated
after a second sequencing run as the first orthogonal Sanger
validations were themselves incorrect. 17 of the NGS variants
would have been considered false positives if a single round of
Sanger sequencing were used as validation criteria. Zheng et al.
(2019) were instead able to validate 98 high-quality NGS variants
by mass spectrometry but not by Sanger sequencing, being some
of those variants characterized by the presence of a homopolymer
at the 100-bp flanking sequence or within pseudogenes. The
authors suggested that if such practice were used in a clinical
setting, more positive NGS variants would be discarded or
incorrectly designated, when compared to using the NGS data
directly. In fact, PCR-based amplification remains susceptible
to ADO due to different mechanisms, such as private variants
within primer-binding sites or secondary structure formation,
potentially determining false-positive/negative results, heavily
impacting genetic diagnosis of several diseases in the clinical
setting. In addition to that, non-primer-binding-site SNVs have
been demonstrated to have the ability to interfere with the PCR
as well, making the primer designing process more laborious
and time-consuming. Some genomic regions are also extremely
difficult to amplify and might not yield high-quality Sanger
results even after multiple attempts, thus possibly rendering
the Sanger validation of a high-quality NGS variant not an
adequate support. NGS still remains susceptible to errors, but,
in our experience and according to those of many laboratories
around the world, variants above the technology-dependent
quality threshold are confirmed by Sanger in almost 100%
of cases. Our study demonstrated that in case of discrepancy
between a high-quality NGS variant and the subsequent Sanger
validation, NGS call should not be a priori assumed to
represent the source of the error. On the other hand, NGS
approaches [targeted/whole-exome (WES)/genome sequencing
(WGS)] exhibit some limitations, as they are characterized by
a lack of uniformity in sequencing depth. In addition, due to
capture of probe design matching the reference sequencing,
preferentially enrichment of reference allele might represent a
further NGS bias. Moreover, a further limitation of the NGS
approach might be represented by the possible presence of false
negatives (although reduced with the progressive improvement
in experimental/computational analysis procedures) and in
turn lack of information concerning genetic variants clinically
relevant, even though standardized criteria are usually adopted
(Sims et al., 2014; LaDuca et al., 2017; Dunn et al., 2018).
Moreover, certain types of variants (copy number variations,
large genomic rearrangements) remain difficult to detect by
NGS, but experimental workflows, bioinformatic tools, and open-
source software are being developed and constantly updated in
order to overcome that issue (Shen and Seshan, 2016; Anwar
et al., 2020; Han et al., 2020). Our paper is not designed to identify
quality thresholds, due to limited number of genes investigated
as compared to WES/WGS; nevertheless, further work of the
scientific community on this task is needed. Hence, the necessity
rises to determine a standardized, high-quality threshold that
could be also established by reviewed International Guidelines for
clinical genetic testing using NGS, thus possibly limiting Sanger
confirmation to risk avoidance purposes (borderline conditions
of variant quality parameters). This approach must be also
weighed against increased cost and time of the genetic test
and the potential failure to confirm a very high-quality NGS
variant because of difficulties (ADO, unpredictable presence of
private variants on primer-binding regions) of direct sequencing
whose designation as “gold standard” should be reconsidered
especially in light of the constantly implemented and accurate
high-throughput technologies.
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